Biologics are part of a growing class of medications that are very complex and expensive to manufacture, but highly effective in treating certain diseases. Biosimilars are essentially a “copy” of a biologic with minimal clinical differences. However, due to the complex manufacturing process, biosimilars can never be completely identical to biologics. Biosimilars offer a unique advantage primarily in cost savings compared to branded versions, and their availability is shifting the pharmaceutical landscape. MD Analytics recently conducted a poll to understand awareness and perceptions of Biosimilars among Canadian physicians.
Biologic Drugs and Biosimilars. Healthcare Triage. 5 Jan. 2016. Web. 8 Nov. 2016.
Biosimilars Versus Generics. Web. 08 Nov. 2016.
Linde, Damon Van Der. “Biosimilars on the Cusp of Making Waves in Canada’s Pharmaceutical Sector.” Financial Post Biosimilars on the Cusp of Making Waves in Canadas Pharmaceuticalsector Comments. Financial Post, 31 Dec. 2015. Web. 08 Nov. 2016.
Ossola, Alexandra. “What Is A Biosimilar Drug?” Popular Science. Popular Science, 19 Apr. 2016. Web. 08 Nov. 2016.